This Heart Health Month, A Renewed Commitment to Driving Innovation in AFib Treatment
February is Heart Health Month – an opportunity to educate our friends, loved-ones and colleagues about the importance of taking care of our hearts.??
At Biosense Webster, we are focused on advancing treatments for a specific type of heart disease – Atrial Fibrillation – a condition which causes the heart to beat irregularly and affects about 38 million people globally.? #AFib can increase a person’s risk for failure and stroke.
Over the past decade, significant advancements have been made in how AFib can be treated with a minimally-invasive procedure called catheter ablation. Through the collaboration of scientists, engineers, and physicians, we’ve seen meaningful innovations in catheter design, mapping, software and energy sources, all of which have contributed to improved patient care. As one example, procedure time for catheter ablations has gone from 3.5 hours in the past to less than an hour today. Today’s technology and approaches enable electrophysiologists (#EPeeps) to achieve 80% success rates or more. In addition, catheter ablation has been shown to reduce the risk of disease progression over standard medical therapy.
One of the most exciting advancements we’ve seen in this field recently is the emergence of Pulsed Field Ablation (PFA) as a new modality for cardiac ablation.? While it’s still in the early stages, research thus far has shown promise for safety, efficacy, and efficiency.? PFA has the potential to widen access for patients seeking AFib ablation.?
Biosense Webster is proud to have been a leader in this field for decades, collaborating with #EPeeps to not only drive innovation in technology, but also in approaches. We are committed to advancing an integrated ecosystem of solutions that enable safer, more efficient and more effective procedures, supporting healthcare professionals in delivering better patient outcomes, and helping more people with AFib live the lives they want.
#mycompany #JNJMedTechProud